TUSTIN, CA--(Marketwire - April 21, 2010) - Through its US-based subsidiary AMDL Diagnostics Inc., Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) announced today it will be presenting at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 4-8, 2010. ASCO is the world’s leading professional organization representing physicians who care for people with cancer. With more than 28,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals.
AMDL Diagnostics will feature its Onko-Sure™ in vitro diagnostic (IVD) cancer test to conference attendees on the exhibition floor and in private briefings. The 2010 ASCO Annual Meeting will focus on advancing quality of clinical oncology through Innovation. More than 30,000 cancer specialists from around the world will gather at the meeting to discuss the latest innovations in research, quality, practice and technology in cancer.
Mr. Douglas MacLellan, CEO of Radient Pharmaceuticals, commented, “This is an extraordinary opportunity for RPC to present its USFDA approved Onko-Sure™ cancer diagnostic test to practicing oncologists from international countries across the globe. RPC’s goal is to communicate the important role Onko-Sure can play in the screening, detection, and monitoring of cancer for cancer patients. We continue to expand RPC’s presence in both the worldwide private and public healthcare markets, addressing the growing cancer challenge.”
Radient Pharmaceuticals’ subsidiary AMDL Diagnostics Inc. will provide additional updates regarding their participation at ASCO via their website www.radient-pharma.com.
Onko-Sure™ is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure™ is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test.
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic and therapeutic products. Visit www.Radient-Pharma.com for additional information.
About ASCO
ASCO is the world’s leading professional organization representing physicians who care for people with cancer. With more than 28,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. For ASCO information and resources, visit www.asco.org/presscenter. Patient-oriented cancer information is available at www.cancer.net.
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company’s operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Radient Pharma Contact:
Kristine Szarkowitz
Director-Investor Relations
Email Contact
(Tel : ) 206.310.5323
Digg this
Bookmark with del.icio.us
Add to Newsvine
Technorati: 
